DEFINING TOMORROW'S VASCULAR STRATEGIES
×
Register now to R3i !
Become a member to receive our newsletter and get unrestricted access to downloadable slidekits...
Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
The Initiative

Prof. Paul Dodson

Prof. Paul Dodson
Heart of England Foundation Trust
Birmingham, UK
 
Current position
 
  Associate Professor,  Warwick Medical School & Consultant Physician in Medicine, Diabetes and Endocrinology, Medical Ophthalmology, Birmingham Heartlands and Solihull NHS Trust (Teaching). , and University Hospital Birmingham Foundation Trust. Clinical Lead for Birmingham & Black Country (BBC) SHA, South and East, Diabetic Retinopathy  Screening Programmes (UK
 
  Honorary Senior Clinical Lecturer, University of Birmingham, UK
 
  Honorary Consultant Physician, Birmingham and Midland Eye
Centre, Birmingham, UK
 
Past position
 
Aug 1989 Consultant Physician, Diabetes, Endocrinology and Medical Ophthalmology, Birmingham Heartlands and Solihull Hospital NHS Trust
1986 - 1987 Acting Consultant Physician, General Medicine and Gastroenterology
Dudley Road Hospital, Birmingham.
1982 - 1989 Senior Registrar (Drs. R. F. Fletcher and K. G. Taylor), General Medicine, Diabetes, Endocrinology, Medical Ophthalmology, Dudley Road Hospital, Birmingham and Birmingham and Midlands Eye Hospital.
1979 - 1981 Research Fellow (for Prof. D. J. Galton,  Mr.A.M.Hamilton, Mr. R.Blach,  Dr.A.Winder) Diabetes, Lipids, Medical Ophthalmology and General Medicine, St. Bartholomew’s Hospital and Moorfield’s Eye Hospital,London.
1977 - 1981 Registrar (for Dr. E. V. Cox), General Medicine, Diabetes and Gastroenterology, Royal Berkshire Hospital, Reading.
1977 Senior House Officer, Neurology, Southampton General Hospital
1976 Senior House Officer, Obstetrics and Gynaecology, Southampton General Hospital
Senior House Officer, Infectious Diseases and General Medicine
Rochford General Hospital
1975 House Surgeon, Rochford General Hospital
House Physician, Rochford General Hospital
 
Scientific training
 
1968 - 1974 The Medical School, St. Bartholomew’s Hospital, London EC1, UK
1974 MRCS (Eng.) LRCP (London)
1975 MB, BS (London)
1979 MRCP (UK)
1984 MD (London)
1994 FRCP
 
Professional Associations
 
  Diabetes UK
  Medical Research Society
  EASD Nutrition Study Group
  Royal College of Ophthalmologists
  Royal College of Physicians
  British Hypertension Society
  British Hyperlipidaemia Association
  Medical Ophthalmological Society (Founder)
 
Publications
 
  • Winder AF, Dodson PM, Galton DJ. Ophthalmological complications of the hypertriglyceridaemias. Transactions of the Ophthalmological Societies of the UK  1980; 100:119-22
  • Dodson PM, Galton DJ and Winder AF. Retinal vascular abnormalities in the hyperlipidaemias.Transactions of the Ophthalmological Societies of the UK 1981;10:17-21
  • Stocks J, Holdsworth G, Dodson PM and Galton DJ. An abnormal triglyceride rich lipoprotein carrying excess apolipoprotein C-II. Atherosclerosis 1981;38:1-9
  • Galton DJ, Holdsworth G, Stock J. Dodson PM. Variant lipoprotein and their interaction with lipoprotein lipase. In Diabetes Obesity and Hyperlipidaemia  Eds. Crepaldi G, Lefebvre PJ, Galton DJ.  Academic Press, London and New York 1981
  • Galton DJ, Stocks J, Dodson PM, Holdsworth G. Regulation of substrate flow in human adipose tissue in health and disease. Proceedings of German Society of Medicine 1981; 87:1460-8
  • Dodson PM, Humphreys DM (1981). Nutrition Intervention in hypertension and angina.  Western Disease: their emergence and prevention.  Eds. Trowell HC and Burkit D, Arnold, London. Chapter 24:411-20
  • Dodson PM, Stocks J, Holdsworth G, Galton DJ.  High fibre and low fat diets in diabetes mellitus. British Journal of Nutrition 1981;46:289-94
  • Dodson PM. Lipids and antihypertensive therapy. British Journal of Clinical Practice 1981;Suppl.20:17-20
  • Holdsworth G, Stocks J, Dodson PM, Galton DJ. An abnormal triglyceride rich lipoprotein containing excess sialyated apolipoprotein C-III. Journal of Clinical Investigation 1981;69:932-9
  • Dodson PM, Galton DJ, Hamilton AM, Black RK. Retinal vein occlusion and the prevalence of lipoprotein abnormalities. British Journal of Ophthalmology 1982;66:161-4
  • Galton DJ, Stocks J, Dodson PM. Lipoproteins: their role in enzyme regulation. Clinical Biochemistry Reviews 1982,3:377-405
  • Dodson PM, Westwick J, Marks G, Kakkar VV, Galton DJ. B-thromboglobulin and platelet factor four levels in retinal vein occlusion. British Journal of Ophthalmology 1983;67:143-6
  • Dodson PM, Pacy PJ, Beevers M, Bal P, Fletcher RF, Taylor KG. The effects of a high fibre, low fat and low sodium dietary regimen on diabetic hypertensive patients of different ethnic group. Postgraduate Medical Journal 1983;55:21-4
  • Pacy PJ, Dodson PM, Beevers M, Fletcher RF and Taylor KG. The ethnic prevalence of hypertension in a diabetic clinic. Postgraduate Medical Journal 1983;55:56-9
  • Dodson PM and Shine B. Retinal vein occlusion C-reactive protein and arterial hypertension. Acta Ophthalmologica 1984;62:123-30
  • Dodson PM, Kritzinger EE. Risk factors for retinal vein occlusion in young patients (<50 years). Transactions of the Ophthalmological Societies of the UK 1984;104:114-9
  • Dodson PM, Pacy PJ, Bal P, Kubicki AJ, Fletcher RF, Taylor KG. A controlled trial of high fibre, low fat and low sodium diet for mild hypertension in type II diabetic patients. Diabetologia 1984;27:522-6
  • Dodson PM, Pacy PJ. Nutrition and fibre in the hypertensive diabetic subject. Proceedings of Symposium "Dietary fibre in the management of the diabetic" (1984). British Diabetic Association, Medicine Foundation; 49-54
  • Pacy PJ, Dodson PM, Kubicki AJ, Fletcher RF, Taylor KG. Comparison of the hypertensive and metabolic effects of bendrofluazide therapy and a high fibre, low fat diet in diabetic subjects with mild hypertension. Journal of Hypertension 1984;2:215-20
  • Pacy PJ, Dodson PM, Kubicki AJ, Fletcher RF, Taylor KG. Comparison of the hypertensive and metabolic effects of bendrofluazide therapy and a high fibre, low fat diet in diabetic subjects with mild hypertension. Diabetes Research 1984;1:201-7
  • Pacy PJ, Dodson PM, Kubicki AJ, Fletcher RF, Taylor KG. The effects of a high fibre, low fat and low sodium dietary regimen on serum lipid and lipoprotein levels in hypertensive diabetic patients. Diabetic Research 1984;1:159-63
  • Walker JM, Cove DH, Beevers DG, Dodson PM, Leatherdale BA, Fletcher RF, Taylor KG. Cigarette smoking, blood pressure and the control of blood sugar in the development of diabetic retinopathy. Diabetic Research 1985;2:183-6
  • Dodson PM, Kubicki AJ, Taylor KG, Kritzonger EE. Medical conditions underlying recurrence of retinal vein occlusion. British Journal of Ophthalmology 1985;69:493-6
  • Dodson PM, Pacy PJ. Dietary effects on blood pressure in 1515 hypertensive diabetics. Diabetic Nephropathy 1985;4:43-5
  • Dodson PM, Pacy PJ, Cox EV. Four year follow up of the treatment of essential hypertension with a high fibre, low fat and low sodium dietary regimen. Human Nutrition: Clinical Nutrition 1985;39C: 213-20
  • Pacy PJ, Dodson PM, Beevers M, Fletcher RF, Taylor KG. Prevalence of hypertension in white, black and Asian diabetics in a district hospital clinic. Diabetic Medicine 1985;2(2):125-30
  • Pacy PJ, Dodson PM. Nutrition and hypertension. Annuals of Nutrition and Metabolism 1985;125:129-37
  • Pacy PJ, Dodson PM, Kubicki AJ, Fletcher RF, Taylor KG. High cereal fibre, low sodium and low fat diet in white and black diabetics with mild hypertension. Diabetes Research1986;3(6):287-292
  • Pacy PJ, Dodson PM, Kubicki AJ, Bal P, Fletcher RF, Taylor KG. Effects of a high carbohydrate, low sodium and low fat diet in type II diabetics with moderate hypertension. International Journal of Obesity 1986; 10: 43-52
  • Dodson PM. Dietary sodium restriction in the treatment of hypertension. Proc. Nutrition Society 1986;45:267-72
  • Pacy PJ, Taylor MP, Kubicki AJ, Dodson PM. High fibre, low sodium, low fat dietary treatment in diabetic subjects with intermittent claudication. British Journal of Clinical Practice 1986;40:313-7
  • Dodson PM, Kritzinger EE. The management of retinal vein occlusion. British Medical Journal (Leading Article) 1987;295:1434-5
  • Pacy PJ, Dodson PM, Kubicki AJ, Fletcher RF, Taylor KG. Differences in lipid and lipoprotein levels in white, black and Asian non-insulin dependent (type II) diabetics with hypertension. Diabetic Research (1987)(4):187-93
  • Dodson PM. Lipids, lipoproteins and diabetes mellitus. In Diabetes and Heart Disease.  Ed. Taylor KG. Castle House Publications, Kent, UK Chapter 4, pp 61-78 (1987)
  • Dodson PM, Horton RC. The nature of atheroma. Proc. Nutrition Society 1987;46:331-6
  • Dodson PM. Diet in the treatment of hypertension. In: Nutrition and blood pressure. Ed. P Bursyn. John Libbey & Co. Chap 9, 145-162 (1987)
  • Dodson PM, Horton RC. The hypertension of diabetes mellitus: mechanisms and implications. Journal of human Hypertension 1988;1:241-7
  • Dodson PM. Explanation of common retino-vascular abnormalities. Update 1988;37(8):663-8
  • Dodson PM. Medical aspects of retinal vein occlusion. Update 1988;37(8):895-8
  • Dodson PM. Medical aspects of retinal arterial occlusion. Update 1988;37(9):775-80
  • Dodson PM. Medical Aspects of inflammatory eye disease. Update 1988;37(11):1003-8
  • Dodson PM. Medical aspects of optic nerve disorders. Update 1988;37(12):1009-106
  • Cole MD, Dodson PM, Hendeles S. Glaucoma and retinal vein occlusion. British Journal of Ophthalmology 1989;73(9):693-8
  • Dodson PM. Dietary treatment of hypertension. In: Diabetes and Hypertension. Editor Gries A.  Chapter 12 (1989)
  • Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG. Sodium and blood pressure in the hypertensive type II diabetic, randomized blind controlled and cross-over studies of moderate sodium restriction and sodium supplementation. British Medical Journal 1989;298:227-30
  • Shinton R, Dodson PM, Beevers DG. Dietary fat and blood pressure. Journal of Human Hypertension 3:73-8 ( 1989 )
  • Dodson PM, Stephenson J, Dodson JL, Kurnik D, Kritzinger EE,Taylor KG. Randomised blind controlled trial of a high fibre, low fat and low sodium diet in the treatment of mild essential hypertension. Journal of Human Hypertension 1989;3:197-202
  • Cole MD, Dodson PM, Hendeles S. Medical conditions underlying retinal vein occlusion in patients with glaucoma or ocular hypertension. British Journal of Ophthalmology 1989;73:693-8
  • Dodson PM, Stephenson J, Dodson LJ, Kurnik D, Kritzinger EE, Taylor KG, Fletcher RF. Randomised blind controlled trial of a high fibre, low fat and low sodium dietary regimen in mild essential hypertension. Journal of Human Hypertension 1989;3:197-202
  • Dodson PM, Bain SC. Nutritional therapy with regard to weight reduction in diabetes and hypertension Journal of Diabetic Complications 1990;4:91-3
  • Bain SC, Dodson PM. The pharmacological treatment of obesity and diabetes mellitus Chapter 12.  Diabetes Forum Series Vol. IIII. Pharmacology of diabetes 1991
  • Dodson PM. Hypertension and insulin resistance: mechanisms and implications for treatment.  Journal of Human Hypertension 1991;5:349-54
  • Bain SC, Dodson PM. Chronic Cardiovascular Risk Syndrome (Syndrome X). Postgraduate Medical Journal 1991;67:922-7
  • O'Donnell M, Dodson PM. Nutrition and blood pressure in the diabetic patient. Journal of Human Hypertension 1991;5:287-94
  • Dodson PM, Gibson JM. Long term follow up of and underlying medical conditions in patients with Diabetic Exudative Maculopathy. Eye, 1991;5:699-703
  • Bain SC, Dodson PM. Managing the obese patient with hypertension. Treating Overweight Series (Medicom Ltd),1991:1-6
  • Dodson PM, Kritzinger EE, Clough CG. Diabetes Mellitus and retinal vein occlusion in patients of Asian, West Indian and White European Origin. Eye 1992;6:66-8
  • Baxter MA, Dodson PM. Is hypertension a metabolic disease? Treating hypertension (Medicom Ltd),1992
  • Baxter MA, Dodson PM; Free radicals in the pathogenesis of atherosclerosis; Medicographia 1992
  • Dodson PM, Clough CG, Downs SM, Kritzinger EE. Does type II diabetes predispose to retinal
  • vein occlusion? European Journal of Ophthalmology, 3(3):109-13 (1993)
  • Keenan JM, Dodson PM, Kritzinger EE. Are there medical conditions specifically underlying the development of rubeosis in central retinal vein occlusion. Eye1993;7:407-10
  • Keenan JM, Kritzinger EE, Dodson PM. The management of retinal vein occlusion. British Journal of Hospital Medicine 1993; 49 (4): 268-273 and British Journal of  Optometry and Dispensing 1993;1(2);51-6
  • Alcolado JC, Ray K, Baxter M, Edwards CW, Dodson PM. Malignant change in dermatitis artefacta. Postgraduate Medical Journal 1993;69:648-50
  • Alcolado JC, Dodson PM. Anti-hypertensive therapy and serum lipids. Treating Hypertension Series 1993;65:2-6
  • Dodson PM. Lipid lowering and diabetes (Leading Article). Diabetes Reviews 1993;2(3):1
  • Betteridge DJ, Dodson PM, Durring PN et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgraduate Medical Journal;69:359-69 (1993)
  • Eames SC, Dodson PM. Treatment of Diabetic Retinopathy. Diabetes Reviews International 3(3): 5-9 (1994)
  • Talks SJ, Chong NMV, Jones A, Dodson PM. Fibrinogen, cholesterol and smoking as risk factors for non arteritic anterior ischaemic optic neuropathy. Eye 1995;9:85-8
  • Lip GY, Beevers M, Dodson PM, Beevers DG. Severe Hypertension with lone bilateral papilloedema.  A variant of malignant hypertension. Blood Pressure 1995;4:339-42
  • Dodson PM, Lip GYH, Eames SM, Gibson JM, Beevers DG. Hypertensive retinopathy: a review of existing classification systems and a suggestion for a simplified system. Journal of Human Hypertension;10:93-8 (1996)
  • Talks SJ, Good P, Clough CG, Beevers DG, Dodson PM. The acute and long term ocular effects of accelerated hypertension: a clinical and electrophysiological study. Eye;10:321-7 (1996)
  • Jude EB, Dale J, Kumar S, Dodson PM. Treatment of thyrotoxicosis resistant to Carbimazole with corticosteroids. Postgraduate Medical Journal;72:489-91 (1996)
  • Brown AD, Dodson PM, Ainsworth JR. Diagnosis and management of migraine. Postgraduate Medical Journal;313:691 (1996)
  • Dodson PM, Kritzinger EE. Medical cardiovascular treatment trials: relevant to medical ophthalmology in 1997? Eye;11:3-11 (1997)
  • Jude EB, Ryan B, O’Leary BM, Gibson JM, Dodson PM. Pupillary dilatation and driving in diabetic patients. Diabetic Medicine;15:143-7 (1998)
  • Taylor RH, Jones HS, Dodson PM, Hamilton AP, Kritzinger EE, 1997. Diabetic Eye Disease:  A natural history study. Eye;11:547-53
  • Kirwan JF, Tsaloumas MD, Vinall H, Prior P, Kritzinger EE, Dodson PM. Sex Hormone Preparations and Retinal Vein Occlusion. Eye;11:53-6 (1997)
  • Dodson PM. ACE Inhibitors for Diabetic Retinopathy? Diabetes Reviews International 1997;6(4) 1
  • Dodson PM. Screening for Retinopathy. Diabetes Reviews International 1997;6(1):1
  • Bain SC, Rowe BR, Dodson PM. Patient compliance and diabetes control. Lancet 1991;337:1047
  • Dodson PM. Diabetic Retinopathy.  P15 -22.  Chapter 3. MEP Publications  London 1998
  • Chowdhury TA, Kumar S, Barnett AH, Dodson PM. Hypertension in type 2 diabetes.  The dawn of a new evidence based era of treatment. Journal of Human Hypertension;13(12):803-11 (1999)
  • Heward JM, Allahabadia A, Daykin J, Carr-Smith J, Daly A, Armitage M, Dodson PM, Sheppard MC, Barnett AH, Franklyn JA, Gough SCL. Linkage Disequilibrium between the Human Leukocyte Antigen Class II region of the major histocompatibility Complex and Grave’s Disease: Replication using a population case control and family-based study. Journal of Clinical Endocrinology Met 1998;83:3394-7
  • Dodson PM. Hypertension and type 2 diabetes: a new evidence based era of treatment. Diabetes Review International (1999)
  • Smith PR, Bain SC, Good PA, Hattersley AT, Barnett AH, Gibson JM, Dodson PM. Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness due to the mitrochondrial DNA 3243 tRNALeu A to G mutation. Ophthalmology;106:1101-8 (1999)
  • Dodson PM, Gibson JM. The national diabetic retinopathy laser treatment audit:  Implications for clinical practice. Eye;12:1-2 (1998)
  • Dodson PM. Vascular complications of type II diabetes:  A new evidence based era of treatment. Eye News; 5(4):12-6 (1998)
  • Gillow JT, Gibson JM, Dodson PM. Hypertension and diabetic retinopathy - What’s the story? British Journal of Ophthalmology;83:1083-7 (1999)
  • Dodson PM. Evaluating hypertension treatment options. Modern Hypertension Management;1:1 (1999)
  • Butcher A, Dodson PM. Hypertension and the Eye. Modern Hypertension Management;1:1-6 (1999)
  • Heward JM, Allahabadia A, Daykin J, Carr-Smith J, Daly A, Armitage M, Hattersley A, Dodson PM, Sheppard MC, Barnett AH, Franklyn JA, Gough SCL. Association of the large multifunctional proteasome (LMP2) gene with Grave’s disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304-DQB1*02-DQA*0501. Clinical Endocrinology 1999;51:115-8
  • Heward JM, Allahabadia A, Armitage M, Hattersley A, Dodson PM, Macleod K, Carr-Smith J, Daykin J, Daly A, Sheppard MC, Holder RL, Barnett AH, Franklyn JA, Gough SCL. The development of Graves’ disease and the CTLA-4 gene on chromosome 2q33. Journal of Clinical Endocrinology and Metabolism 1999;84:2398-401.
  • Tsaloumas MD, Kirwan J, Vinall H, O’Leary MB, Prior P, Gibson JM, Kritzinger EE, Dodson PM. Nine year follow up study of morbidity and mortality in retinal vein occlusion. Eye;14:821-7 (2000)
  • Chowdhury TA, Tanchel BM, Jaganathan RS, Dodson PM. A toxic testicle. Lancet 2000;355:2046
  • Martin SC, Rauz S, Marr JE, Martin N, Jones AF, Dodson PM. Plasma total homocysteine and retinal vascular disease. Eye;14:590-3 (2000)
  • Butcher A, Dodson PM. Diabetes and the Eye.  Book Chapter. Chapter 9:119-32. Diabetes in old age.  Ed. A Sinclair, Finulane P: Wiley Press (2001)
  • Dodson PM. Retinal Vein Occlusion. Book Chapter.  Ed. Shah P, Murray P. (Bios)  (2002)
  • Dodson PM. Retinal Artery Occlusion. Eye News;8(6):9-14 (2002)
  • Dodson PM. Diabetes Mellitus. Book Chapter in Key Topics in Ophthalmology – 2nd Edition. Ed. Shah P, Murray P. (Bios Scientific Publishers Ltd)  (p 90-97, 2001)
  • Butcher A, Dodson PM. Hypertension and the Eye. Book Chapter. Ed. Shah P, Murray P. (Bios)  (p 135-139, 2001)
  • Butcher A, Dodson PM. Thyroid Eye Disease. Book Chapter. Ed. Shah P, Murray P. (Bios)  (p 315-319, 2001)
  • Dodson PM. Obesity and Hypertension. Modern Hypertension Management 2(4):7-10, 2000)
  • Dodson PM. ACE Inhibitors and Diabetic Retinopathy. Practical Diabetes 16 (8):S5-6 (2000)
  • Butcher A, Dodson PM. Preventing diabetic retinopathy. Dialogue Series:11-4 (2000)
  • Chowdhury TA, Ellis C, Jaganathan R, Dodson PM. Hydronephrosis and a hard neck swelling. Postgraduate Medical Journal; 77(908):409, 418-9 (2000)
  • Denniston A, Dodson PM, Reuser TQR. Thyroid eye disease. Hospital Medicine; 63:152-6 (2002)
  • Dodson PM. Oral agents for retinopathy: from graveyard to hope? Modern Diabetes Management; 2(3):1 (2001)
  • Martin SC, Butcher A, Martin N, Farmer J, Bartlett WA, Jones AF, Dodson PM. Cardiovascular risk assessment in patients with retinal vein occlusion. British Journal Ophthalmology; 86:774-6  (2002)
  • Chowdhury TA, Iyer SJ, Dodson PM. Combined hypertension and diabetes: rewriting the text books. Update 315-9 (2000)
  • Dodson PM. Hypertension and Obesity. Obesity in Practice;2 (4):12-5 (2000)
  • Allahabadia A, Heward JM, Nithiyananthan R, Gibson SM, Reuser TTQ, Dodson PM, Franklyn JA, Gough SCL.  MHC Class II region, CTLA4 gene, and ophthalmopathy in patients with Grave Disease. Lancet;358:984-5 (2001)
  • Dodson PM.  Fibrates for diabetic dyslipidaemia: a revival.  Modern Diabetes Management; 1 (3):1 (2000)
  • Dodson PM. Breast feeding in the genesis of hypertension. Modern Hypertension Management; 3(2):1 (2001)
  • Dodson PM. Antihypertensive drugs and cancer: Case closed? Modern Hypertension Management; 3(4):1 (2001)
  •  Dodson PM. Hypertension and Diabetes: A review of the Evidence base. Book Chapter- Martin Lister Publishing (2002)
  • Dodson PM, Tsaloumas M. Retinal Vein Occlusion. Eye News; 8 (2):16-20 (2002)
  • Dodson PM. Hypertension and Diabetes : Book Chapter in ; Current Medical Research and Opinion; 18(18):s48-s57 (2002)
  • Donaldson M, Dodson PM. Medical therapies for Diabetic retinopathy. Nature Eye;17:550-62 (2003)
  •  Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. Lipids and exudative diabetic maculopathy: potential for therapy? Nature Eye;16(6): 689-93 (2002)
  •  Dodson PM, Haynes J, Starczynski J, Farmer J, Shigdar S, Fegan G, Johnson RJ, Fegan C.   The platelet glycoprotein 1a/11a gene polymorphism C807T/G873A : a novel  risk factor for retinal vein occlusion.  Nature Eye;17:772-7 (2003)
  • Palin SL, Dodson PM. Retinovascular Disease and hormone replacement therapy. Book Chapter in ‘Menopause’, Editor Schneider HPG, Parthenon Publishing  Chapter 44:256-61 (2002)
  • Dodson PM.  Retinal screening (NSF). Modern Diabetes Management 4: S13 (2003)
  • Dodson PM.  New Drugs versus old – lessons from ALLHAT. Modern Hypertension Management; 5(1):1 (2003)
  •  Nithiyananthan R, Dodson PM. Chapter:  Non pharmacological treatment of hypertension and diabetes mellitus. Book:  Hypertension and Diabetes Mellitus. Editor Brian Williams. Martin Dunitz Publishing : chapter 16:267-84 (2003)
  •  Denniston A, Bannerjee P, Gibson J, Dodson PM. Does cardiovascular therapy affect the onset and recurrence of pre-retinal haemorrhage in diabetic eye disease. Nature Eye;18(8);821-5 (2004)
  • Denniston  Aj, Banerjee S, Gibson JM, Dodson PM. Cardiovascular therapies and their role in diabetic eye disease. Diabetic Medicine May;22(5):665-6 (2005)
  • Al-Husainy S, Farmer J, Gibson JM, Dodson PM. Is measurement of blood pressure worthwhile  in the diabetic eye clinic ? Nature Eye;19(3):312-6 (2005)
  • Dodson PM. Diabetic Retinopathy – Book Chapter. MEP Publications (2006)
  • Wright A, Dodson PM. Homocysteine, Folate  and the Eye. Nature Eye (on line advance publication 2008)
  • Wright A, Dodson PM. Diabetic retinopathy without diabetes. Diabetic Medicine;24:1174-5 (2007)
  •  Dodson PM. Diabetic retinopathy: treatment and prevention. Diab Vasc Dis Res. Sep;4 Suppl 3:S9-S11(2007)
  • Colhoun HM, Betteridge DJ, Dodson PM et al. Effect of Atorvastatin on microvascular Outcomes in the collaborative Atorvastatin Diabetes Study ( CARDS ). Diabetes Care (submitted 2008)    
  • Al-Husainy S, Dodson PM, Gibson JM. Pain response in patients undergoing pan retinal photocoagulation by continuous wave Nd-YAG Laser (Nature Eye, on line advance publication 2008)
  • Dodson PM. Diabetic retinopathy; medical management and screening in  ‘Hot topics in diabetes’.  Editor Jiten Vora, Publisher Synergy Press 2008  ISBN 978-1-897859-96-4
  • Dodson PM. Medical Treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering? Practical Diabetes International;25(2):76-9 (2008)
  • Clarke M, Dodson PM. PKC inhibition and diabetic microvascular complications. Best practice & research Clinical Endocrinology  & Metabolism;21(4):573-86 (2007)
  • Dodson PM. Medical treatment of diabetic retinopathy. Chapter. In   ‘Hot Topics in diabetes’. Editor Jiten Vora. Publisher Synergy Press. 2009
  • Dodson PM. Management of diabetic retinopathy; new medical treatments. British Journal of Ophthalmology (for submission 2008)
 
Books
 
  Dodson PM and Barnett AH. Diabetes and Vascular disease
Science Press, 1st Edition (1992) - 2nd Edition (1998) Dodson PM, Gibson JM, Kritzinger EE. Clinical Retinopathies
Chapman and Hall (1995) Dodson PM, Bayly G. Soluble Fibre and Cholesterol Reduction
Publishing Initiatives, Beckenham, Kent (1997) Barnett AH, Dodson PM. Target Organ Damage in Hypertension
Science Press (1997) Barnett AH, Dodson PM. Hypertension and Diabetes
Science Press, 1st Edition (1990) - 2nd Edition (1998) - 3rd Edition (2000) Dodson PM, Barnett AH and O’Gara MG. Shared Care in Diabetes
Science Press Ltd. London (1998) Dodson PM, Barnett AH. Lipids in Primary Care
Magellan (1998) Dodson PM Editor. Diabetic Retinopathy – Screening to Treatment
Oxford Press (in press) (November 2008) HEDRSCRE Team. Atlas of Diabetic Retinopathy Screening
Mardeno (in preparation) (2008)
 
 
Awards
 
1983 Stephen Whittaker Prize
  West Midlands Physicians’ Association
1995 Spencer Walker Price, RCOphth
1997 - ‘B’ Merit award and  renewed for 5 years
 
Research
 
  • Diabetes, Hypertension, Hyperlipidaemia
My initial research was into nutritional effects on blood pressure in hypertensive subjects and diabetics.  My research and clinical career developed with work for my MD thesis on lipoprotein metabolism and medical aspects of retinal vascular disease (London MD, 1984) at St. Bartholomew’s Hospital and Moorfield’s Eye Hospital, London. Grants for a research fellow and nursing staff have been obtained to continue work into prevalence, nutritional effects and therapies for hypertension and hyperlipidaemia in diabetic subjects.  Our group was amongst the first to highlight the high prevalence of hypertension in diabetes subjects, the co-clustering of risk factors, the importance of nutritional manipulation and drug therapies (ACE inhibitors) in diabetic subjects.  Studies on prevalence of lipid and lipoprotein metabolism, relationship to cardiovascular disease and drug therapies (fibrates and statins) have been undertaken. I am a principal investigator for the CARDS study of atorvastatin in primary prevention in diabetic subjects ( 5 year study funded by the DOH and Pfizer).
  • Medical Ophthalmology
My early research stressed the importance of associated medical conditions to retinal vascular disease such that medical assessment and therapy is an integral part of patient management to obtain best final visual outcome and prevent recurrence of retinal vein occlusion in the fellow eye.  Studies on the aetiology of retinal vascular disease have identified platelet function abnormalities, increased inflammatory markers, hypercholesterolaemia, and hyperhomocysteinaemia as therapeutic targets.  Long term follow up studies have been performed suggesting medical benefit of cardiovascular medical therapies as well as steroid therapy in young patients.  Much of this work is incorporated in the draft national guidelines (RCOphth.) on the management of retinal vein occlusions.  A major interest has been in the aetiology, risk factors, medical management, and screening of diabetic retinopathy.  We were one of the first groups to highlight increasing LDL cholesterol as a risk for exudative maculopathy, the medical factors underlying ischaemic maculopathy, and the importance of non-diabetic retinopathy causes of severe visual impairment in diabetic subjects.  These observations led to the East Birmingham Diabetic Eye Screening Service initiated in 1993 using trained optometrists, the success of which has led to this approach being incorporated Pan-Birmingham, and the protocol formed the basis of the British Diabetic Association Optometry screening recommendations.  I am subsequently a member of the National Diabetic Retinopathy Committee, and chair of its Training and Accreditation  committee.
  • Ongoing Research
Major projects include the potential of medical therapies for microvascular disease, with protein-kinase C inhibition and inhibition of growth hormone and IGF-1 by a long acting octreotide formulation.  Our centre is one of four in the UK that I have set up, with a research team (optometry, nursing, photographic, physician and ophthalmology) that is able to perform these exciting studies.  In March 2002 my group is one of the major centres for a therapeutic trial specifically of diabetic macula oedema, and co-ordinator of studies of surrogate markers for macula oedema or application to diabetic retinopathy screening programmes ( Chairman of the UK board).  I am currently  the principle investigator for studies of Diabetic Maculopathy for the protein kinase C-inhibitor therapy.  The results of our large initial randomised trials in retinopathy were positive, and I am the principal investigator for the continuing  major trial programme. ( 2004 – 2007). Other projects funded include angiogenesis of angiotensin receptor blockade, thrombophilic factors and vascular disease, and statin therapy in the primary prevention of vascular disease in diabetic patients. Our group have recently identified a possible gene marker for retinal vein occlusion, and I am an investigator into genetics of thyroid eye disease (Lead  Dr. S.Gough )
Research has been initiated on aspects of diabetic retinopathy screening, including prospective follow-up of a large cohort of diabetic patients with micro-aneuryms in the macula region to identify the natural history, and guide the correct screening intervals. Studies have recently been completed into blood pressure measurement and clinical use in the diabetic eye clinic, aspirin and relationship to vitreous haemorrhage, and methodologies of laser treatment.